ABT logo

Abbott Laboratories (ABT) Free cash flow

annual FCF:

$6.35B+$1.29B(+25.54%)
December 31, 2024

Summary

  • As of today (April 18, 2025), ABT annual free cash flow is $6.35 billion, with the most recent change of +$1.29 billion (+25.54%) on December 31, 2024.
  • During the last 3 years, ABT annual FCF has fallen by -$2.30 billion (-26.56%).
  • ABT annual FCF is now -26.56% below its all-time high of $8.65 billion, reached on December 31, 2021.

Performance

ABT Free cash flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherABTcash flow metrics

quarterly FCF:

$2.15B-$1.00M(-0.05%)
December 31, 2024

Summary

  • As of today (April 18, 2025), ABT quarterly free cash flow is $2.15 billion, with the most recent change of -$1.00 million (-0.05%) on December 31, 2024.
  • Over the past year, ABT quarterly FCF has dropped by -$135.00 million (-5.91%).
  • ABT quarterly FCF is now -31.13% below its all-time high of $3.12 billion, reached on December 31, 2020.

Performance

ABT quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherABTcash flow metrics

TTM FCF:

$6.35B-$135.00M(-2.08%)
December 31, 2024

Summary

  • As of today (April 18, 2025), ABT TTM free cash flow is $6.35 billion, with the most recent change of -$135.00 million (-2.08%) on December 31, 2024.
  • Over the past year, ABT TTM FCF has increased by +$1.29 billion (+25.54%).
  • ABT TTM FCF is now -31.81% below its all-time high of $9.31 billion, reached on September 30, 2021.

Performance

ABT TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

Range

Earnings dates

OtherABTcash flow metrics

Free cash flow Formula

FCF = Cash From Operations − CAPEX

ABT Free cash flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+25.5%-5.9%+25.5%
3 y3 years-26.6%-5.9%+25.5%
5 y5 years+41.2%-5.9%+25.5%

ABT Free cash flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-26.6%+25.5%-7.1%+242.6%-25.6%+41.4%
5 y5-year-26.6%+41.2%-31.1%+505.1%-31.8%+41.9%
alltimeall time-26.6%+1564.3%-31.1%+671.4%-31.8%>+9999.0%

Abbott Laboratories Free cash flow History

DateAnnualQuarterlyTTM
Dec 2024
$6.35B(+25.5%)
$2.15B(-0.0%)
$6.35B(-2.1%)
Sep 2024
-
$2.15B(+50.6%)
$6.49B(+14.7%)
Jun 2024
-
$1.43B(+127.6%)
$5.65B(+14.8%)
Mar 2024
-
$627.00M(-72.5%)
$4.92B(-2.7%)
Dec 2023
$5.06B(-35.2%)
$2.28B(+73.3%)
$5.06B(+12.6%)
Sep 2023
-
$1.32B(+89.2%)
$4.49B(-18.1%)
Jun 2023
-
$696.00M(-8.8%)
$5.49B(-19.6%)
Mar 2023
-
$763.00M(-55.5%)
$6.82B(-12.6%)
Dec 2022
$7.80B(-9.8%)
$1.72B(-25.8%)
$7.80B(-8.6%)
Sep 2022
-
$2.31B(+13.9%)
$8.54B(+0.9%)
Jun 2022
-
$2.03B(+16.5%)
$8.47B(+3.9%)
Mar 2022
-
$1.74B(-28.9%)
$8.15B(-5.7%)
Dec 2021
$8.65B(+51.1%)
$2.45B(+9.5%)
$8.65B(-7.2%)
Sep 2021
-
$2.24B(+30.6%)
$9.31B(+7.8%)
Jun 2021
-
$1.72B(-23.4%)
$8.64B(+13.6%)
Mar 2021
-
$2.24B(-28.2%)
$7.61B(+32.9%)
Dec 2020
$5.72B(+27.3%)
$3.12B(+98.7%)
$5.72B(+24.8%)
Sep 2020
-
$1.57B(+130.9%)
$4.59B(+0.5%)
Jun 2020
-
$680.00M(+91.5%)
$4.56B(+2.0%)
Mar 2020
-
$355.00M(-82.1%)
$4.48B(-0.5%)
Dec 2019
$4.50B(-8.3%)
$1.98B(+28.1%)
$4.50B(+17.9%)
Sep 2019
-
$1.55B(+161.3%)
$3.81B(-6.9%)
Jun 2019
-
$592.00M(+57.0%)
$4.10B(-8.0%)
Mar 2019
-
$377.00M(-71.0%)
$4.45B(-9.3%)
Dec 2018
$4.91B(+10.6%)
$1.30B(-29.0%)
$4.91B(+0.1%)
Sep 2018
-
$1.83B(+93.3%)
$4.90B(+1.8%)
Jun 2018
-
$946.00M(+13.6%)
$4.82B(-3.0%)
Mar 2018
-
$833.00M(-35.7%)
$4.97B(+12.0%)
Dec 2017
$4.43B(+113.0%)
$1.29B(-25.7%)
$4.43B(+11.1%)
Sep 2017
-
$1.74B(+58.9%)
$3.99B(+26.5%)
Jun 2017
-
$1.10B(+262.9%)
$3.15B(+16.0%)
Mar 2017
-
$302.00M(-64.5%)
$2.72B(+30.6%)
Dec 2016
$2.08B(+12.2%)
$851.00M(-6.0%)
$2.08B(+15.0%)
Sep 2016
-
$905.00M(+36.7%)
$1.81B(+7.2%)
Jun 2016
-
$662.00M(-297.0%)
$1.69B(-3.6%)
Mar 2016
-
-$336.00M(-157.9%)
$1.75B(-5.5%)
Dec 2015
$1.86B(-28.6%)
$580.00M(-26.0%)
$1.86B(-16.7%)
Sep 2015
-
$784.00M(+8.1%)
$2.23B(-5.9%)
Jun 2015
-
$725.00M(-411.2%)
$2.37B(+3.6%)
Mar 2015
-
-$233.00M(-124.5%)
$2.28B(-12.1%)
Dec 2014
$2.60B(+19.2%)
$951.00M(+2.9%)
$2.60B(-12.5%)
Sep 2014
-
$924.00M(+43.9%)
$2.97B(+29.7%)
Jun 2014
-
$642.00M(+692.6%)
$2.29B(+10.4%)
Mar 2014
-
$81.00M(-93.9%)
$2.07B(-4.8%)
Dec 2013
$2.18B(-71.0%)
$1.32B(+439.6%)
$2.18B(+10.4%)
Sep 2013
-
$245.00M(-42.5%)
$1.97B(-58.2%)
Jun 2013
-
$426.00M(+129.0%)
$4.72B(-20.5%)
Mar 2013
-
$186.00M(-83.3%)
$5.93B(-21.1%)
Dec 2012
$7.52B(+0.5%)
$1.12B(-62.6%)
$7.52B(-0.1%)
Sep 2012
-
$2.99B(+82.1%)
$7.53B(+5.4%)
Jun 2012
-
$1.64B(-7.3%)
$7.14B(-6.4%)
Mar 2012
-
$1.77B(+57.2%)
$7.63B(+2.0%)
Dec 2011
$7.48B(-3.1%)
$1.13B(-56.7%)
$7.48B(-10.7%)
Sep 2011
-
$2.60B(+22.2%)
$8.38B(+3.2%)
Jun 2011
-
$2.13B(+31.5%)
$8.12B(+0.7%)
Mar 2011
-
$1.62B(-20.0%)
$8.06B(+4.4%)
Dec 2010
$7.72B(+24.8%)
$2.03B(-13.6%)
$7.72B(+6.0%)
Sep 2010
-
$2.34B(+12.9%)
$7.28B(-4.7%)
Jun 2010
-
$2.07B(+62.4%)
$7.64B(+8.9%)
Mar 2010
-
$1.28B(-19.5%)
$7.02B(+13.4%)
Dec 2009
$6.19B(+8.4%)
$1.59B(-41.2%)
$6.19B(+11.1%)
Sep 2009
-
$2.70B(+86.2%)
$5.57B(+6.2%)
Jun 2009
-
$1.45B(+224.9%)
$5.24B(+1.2%)
Mar 2009
-
$446.57M(-53.9%)
$5.18B(-9.2%)
Dec 2008
$5.71B(+61.8%)
$967.99M(-59.3%)
$5.71B(+6.5%)
Sep 2008
-
$2.38B(+71.4%)
$5.36B(+29.7%)
Jun 2008
-
$1.39B(+42.8%)
$4.13B(+9.5%)
Mar 2008
-
$972.17M(+56.5%)
$3.77B(+6.9%)
Dec 2007
$3.53B
$621.31M(-46.0%)
$3.53B(-9.1%)
Sep 2007
-
$1.15B(+11.8%)
$3.88B(+5.9%)
DateAnnualQuarterlyTTM
Jun 2007
-
$1.03B(+41.5%)
$3.66B(-4.4%)
Mar 2007
-
$727.17M(-25.4%)
$3.83B(-4.0%)
Dec 2006
$3.99B(+0.6%)
$974.42M(+4.5%)
$3.99B(-1.6%)
Sep 2006
-
$932.55M(-22.1%)
$4.06B(-5.4%)
Jun 2006
-
$1.20B(+35.0%)
$4.29B(-7.9%)
Mar 2006
-
$886.87M(-14.7%)
$4.65B(+17.3%)
Dec 2005
$3.97B(+24.9%)
$1.04B(-10.6%)
$3.97B(+15.6%)
Sep 2005
-
$1.16B(-25.7%)
$3.43B(+24.2%)
Jun 2005
-
$1.56B(+684.0%)
$2.76B(+15.9%)
Mar 2005
-
$199.58M(-60.4%)
$2.38B(-24.9%)
Dec 2004
$3.18B(+26.9%)
$503.77M(+2.0%)
$3.18B(+5.6%)
Sep 2004
-
$493.86M(-58.4%)
$3.01B(-7.9%)
Jun 2004
-
$1.19B(+19.6%)
$3.26B(+15.1%)
Mar 2004
-
$991.75M(+194.8%)
$2.84B(+13.3%)
Dec 2003
$2.50B(-13.3%)
$336.44M(-55.2%)
$2.50B(-16.0%)
Sep 2003
-
$750.62M(-1.0%)
$2.98B(+5.6%)
Jun 2003
-
$757.88M(+15.2%)
$2.82B(+4.2%)
Mar 2003
-
$658.10M(-19.1%)
$2.71B(-6.3%)
Dec 2002
$2.89B(+20.1%)
$813.33M(+37.5%)
$2.89B(+11.1%)
Sep 2002
-
$591.32M(-8.1%)
$2.60B(-6.6%)
Jun 2002
-
$643.29M(-23.3%)
$2.78B(+8.6%)
Mar 2002
-
$838.70M(+59.7%)
$2.56B(+6.5%)
Dec 2001
$2.40B(+16.4%)
$525.29M(-32.1%)
$2.40B(+2.5%)
Sep 2001
-
$774.16M(+83.5%)
$2.34B(+14.3%)
Jun 2001
-
$421.90M(-38.1%)
$2.05B(-21.3%)
Mar 2001
-
$681.79M(+46.1%)
$2.61B(+26.3%)
Dec 2000
$2.06B(+19.1%)
$466.55M(-2.9%)
$2.06B(+42.2%)
Sep 2000
-
$480.48M(-50.9%)
$1.45B(-14.7%)
Jun 2000
-
$978.55M(+608.3%)
$1.70B(+34.7%)
Mar 2000
-
$138.16M(-195.0%)
$1.26B(-27.1%)
Dec 1999
$1.73B(+12.7%)
-$145.42M(-119.9%)
$1.73B(-17.2%)
Sep 1999
-
$730.82M(+35.4%)
$2.09B(+112.0%)
Jun 1999
-
$539.77M(-11.3%)
$987.86M(-34.3%)
Mar 1999
-
$608.23M(+181.8%)
$1.50B(-2.3%)
Dec 1998
$1.54B(+6.0%)
$215.80M(-157.4%)
$1.54B(+2.9%)
Sep 1998
-
-$375.94M(-135.6%)
$1.49B(-16.2%)
Jun 1998
-
$1.05B(+64.0%)
$1.78B(+36.3%)
Mar 1998
-
$643.00M(+272.3%)
$1.31B(-9.8%)
Dec 1997
$1.45B(+1.2%)
$172.70M(-300.6%)
$1.45B(-8.3%)
Sep 1997
-
-$86.11M(-114.9%)
$1.58B(-24.0%)
Jun 1997
-
$579.28M(-26.2%)
$2.08B(+17.9%)
Mar 1997
-
$784.63M(+158.8%)
$1.76B(+23.0%)
Dec 1996
$1.43B(-27.1%)
$303.13M(-26.4%)
$1.43B(-7.0%)
Sep 1996
-
$411.87M(+56.2%)
$1.54B(-6.5%)
Jun 1996
-
$263.70M(-42.0%)
$1.65B(-13.8%)
Mar 1996
-
$454.40M(+10.5%)
$1.91B(-2.7%)
Dec 1995
$1.97B(-11.1%)
$411.18M(-20.8%)
$1.97B(-8.4%)
Sep 1995
-
$519.18M(-1.5%)
$2.15B(-3.6%)
Jun 1995
-
$526.89M(+3.7%)
$2.23B(+2.5%)
Mar 1995
-
$508.33M(-14.1%)
$2.17B(-1.7%)
Dec 1994
$2.21B(+19.8%)
$591.69M(-1.5%)
$2.21B(-20.7%)
Sep 1994
-
$600.46M(+26.9%)
$2.79B(+10.8%)
Jun 1994
-
$473.14M(-13.5%)
$2.52B(+16.0%)
Mar 1994
-
$546.85M(-53.2%)
$2.17B(+17.5%)
Dec 1993
$1.85B(+384.0%)
$1.17B(+255.8%)
$1.85B(+109.7%)
Sep 1993
-
$328.60M(+162.9%)
$880.80M(+54.3%)
Jun 1993
-
$125.00M(-44.2%)
$571.00M(+3.0%)
Mar 1993
-
$224.20M(+10.4%)
$554.30M(+45.3%)
Dec 1992
$381.60M(-44.1%)
$203.00M(+979.8%)
$381.60M(+18.5%)
Sep 1992
-
$18.80M(-82.6%)
$322.00M(-39.2%)
Jun 1992
-
$108.30M(+110.3%)
$530.00M(-17.6%)
Mar 1992
-
$51.50M(-64.1%)
$643.10M(-5.8%)
Dec 1991
$682.60M(+22.0%)
$143.40M(-36.8%)
$682.60M(-6.4%)
Sep 1991
-
$226.80M(+2.4%)
$729.00M(+1.5%)
Jun 1991
-
$221.40M(+143.3%)
$718.50M(+22.3%)
Mar 1991
-
$91.00M(-52.1%)
$587.70M(+5.0%)
Dec 1990
$559.50M(+44.6%)
$189.80M(-12.3%)
$559.50M(+51.3%)
Sep 1990
-
$216.30M(+138.7%)
$369.70M(+141.0%)
Jun 1990
-
$90.60M(+44.3%)
$153.40M(+144.3%)
Mar 1990
-
$62.80M
$62.80M
Dec 1989
$386.80M
-
-

FAQ

  • What is Abbott Laboratories annual free cash flow?
  • What is the all time high annual FCF for Abbott Laboratories?
  • What is Abbott Laboratories annual FCF year-on-year change?
  • What is Abbott Laboratories quarterly free cash flow?
  • What is the all time high quarterly FCF for Abbott Laboratories?
  • What is Abbott Laboratories quarterly FCF year-on-year change?
  • What is Abbott Laboratories TTM free cash flow?
  • What is the all time high TTM FCF for Abbott Laboratories?
  • What is Abbott Laboratories TTM FCF year-on-year change?

What is Abbott Laboratories annual free cash flow?

The current annual FCF of ABT is $6.35B

What is the all time high annual FCF for Abbott Laboratories?

Abbott Laboratories all-time high annual free cash flow is $8.65B

What is Abbott Laboratories annual FCF year-on-year change?

Over the past year, ABT annual free cash flow has changed by +$1.29B (+25.54%)

What is Abbott Laboratories quarterly free cash flow?

The current quarterly FCF of ABT is $2.15B

What is the all time high quarterly FCF for Abbott Laboratories?

Abbott Laboratories all-time high quarterly free cash flow is $3.12B

What is Abbott Laboratories quarterly FCF year-on-year change?

Over the past year, ABT quarterly free cash flow has changed by -$135.00M (-5.91%)

What is Abbott Laboratories TTM free cash flow?

The current TTM FCF of ABT is $6.35B

What is the all time high TTM FCF for Abbott Laboratories?

Abbott Laboratories all-time high TTM free cash flow is $9.31B

What is Abbott Laboratories TTM FCF year-on-year change?

Over the past year, ABT TTM free cash flow has changed by +$1.29B (+25.54%)
On this page